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A B S T R A C T
The aim of the current planning study is to evaluate the ability of gadoxetate disodium-enhanced mag-
netic resonance imaging (EOB-MRI)–guided stereotactic body radiation therapy (SBRT) planning by using
intensity-modulated radiation therapy (IMRT) techniques in sparing the functional liver tissues during
SBRT for hepatocellular carcinoma. In this study, 20 patients with hepatocellular carcinoma were en-
rolled. Functional liver tissues were deﬁned according to quantitative liver-spleen contrast ratios ≥ 1.5
on a hepatobiliary phase scan. Functional images were fused with the planning computed tomography
(CT) images; the following 2 SBRT plans were designed using a “step-and-shoot” static IMRT technique
for each patient: (1) an anatomical SBRT plan optimization based on the total liver; and (2) a functional
SBRT plan based on the functional liver. The total prescribed dose was 48 gray (Gy) in 4 fractions. Do-
simetric parameters, including dose to 95% of the planning target volume (PTV D95%), percentages of total
and functional liver volumes, which received doses from 5 to 30 Gy (V5 to V30 and fV5 to fV30), and
mean doses to total and functional liver (MLD and fMLD, respectively) of the 2 plans were compared.
Compared with anatomical plans, functional image-guided SBRT plans reducedMLD (mean: plan A, 5.5 Gy;
and plan F, 5.1 Gy; p < 0.0001) and fMLD (mean: plan A, 5.4 Gy; and plan F, 4.9 Gy; p < 0.0001), as well
as V5 to V30 and fV5 to fV30. No differences were noted in PTV coverage and nonhepatic organs at risk
(OARs) doses. In conclusion, EOB-MRI–guided SBRT planning using the IMRT technique may preserve
functional liver tissues in patients with hepatocellular carcinoma (HCC).
© 2017 American Association of Medical Dosimetrists.
Introduction
Hepatocellular carcinoma (HCC) is the sixthmost common cancer
and the third leading cause of cancer-related death in the world.1
Curative therapy for early-stage HCC involves surgeries such as re-
section or transplantation.2,3 However, only 10% to 30% of patients
with HCC are eligible for surgery.4 Accordingly, for patients with HCC
with liver dysfunction, underlying cirrhosis, or multifocal tumors,
locoregional therapies such as radiofrequency ablation or transarterial
chemoembolization are recommended.3 Although radiation therapy
has not been accepted as a therapeutic option for HCC according
to the Barcelona Clinic Liver Cancer staging system, several studies
have reported good treatment outcomes with stereotactic body ra-
diation therapy (SBRT) for HCC.5-7 SBRT is a highly conformal
radiotherapy (RT) technique used for extracranial tumors, which de-
livers a very high dose per fraction in a short time while limiting
the exposure to adjacent normal tissues.8,9
Challenges of HCC treatment include limited liver function in
some patients; in previous studies, nonclassic radiation-induced liver
disease (RILD) was more common in patients with poor liver func-
tion (hepatitis B infection and Child-Pugh classes B and C).10,11
Therefore, SBRT to the liver should be cautiously planned to prevent
RILD. Moreover, the incidence of RILD is strongly correlated with
irradiated liver volumes12 and mean liver doses.13 Hence, precise as-
sessments of liver function are critical to minimize irradiated
volumes and mean doses to functional liver tissues.
Functional imaging techniques are used during RT planning and
treatment to minimize irradiated volumes and mean doses to func-
tional tissues while delivering highly conformal doses to the tumor.14
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Functional imaging modalities, such as functional magnetic reso-
nance imaging (MRI),15 [18F]-ﬂuorodeoxyglucose positron emission
tomography,16 single-photon emission computed tomography
(SPECT) using 99mTc-labeled iminodiacetic acid,17 and 4-dimensional
computed tomography (CT),18 have been used during radiation treat-
ment planning. However, functional image-guided RT planning and
treatment for HCC remain poorly validated. A few studies investi-
gated the eﬃcacy of SPECT-based RT for HCC19,20; however, in clinical
practice, SPECT liver imaging for liver SBRT is implemented in several
institutions only.
Recent studies indicate that gadoxetate disodium (EOB; EOB
Primovist; Bayer Yakuhin Ltd., Osaka, Japan)-enhanced MRI (EOB-
MRI) is effective for detecting hepatic lesions and may indicate
hepatic function.21,22 Some studies have demonstrated the clinical
utility of EOB-MRI as a predictive parameter to assess the changes
in hepatic function after SBRT.23,24 Thus, it is a promising imaging
technique for assessing liver dysfunction and predicting changes in
hepatic function after SBRT. Therefore, we believe that the EOB-
MRI–guided liver functional imagingmodality can be applied to SBRT
for liver cancer to spare the functional liver region using intensity-
modulated radiation therapy (IMRT) planning and lead to safer and
more eﬃcacious treatment.
Here we investigated the ability of EOB-MRI–guided SBRT plan-
ning using IMRT techniques to reduce functional liver mean dose
and functional liver volumes, which received doses from 5 to 30 Gy.
Methods and Materials
Patient characteristics
A total of 20 subjects were recruited after curative SBRT for HCC at Hiroshima
University Hospital between May 2009 and May 2013. The study was approved by
the university’s Human Ethics Review Committee, and written informed consent was
obtained from all patients.
The inclusion criteria of our institution for curative SBRT for HCC are as follows:
(1) Eastern Cooperative Oncology Group Performance Status of 0 to 2; (2) Child-
Pugh score A or B; (3) < 3 HCC nodules, each less than 5 cm in diameter, with or
without vascular invasion; (4) luminal gastrointestinal tract should be far from tumor
more than 2 cm; (5) inoperability; and (6) unsuitability for radiofrequency abla-
tion because of tumor location, invisibility on ultrasonography, or bleeding tendency.
The exclusion criteria were uncontrolled ascites and gastrointestinal tract-
adjacent tumor.
Patient and tumor characteristics are summarized in Table 1.
EOB-MRI acquisition
MRI was performed before SBRT planning for all patients using 1.5-T imagers
(Signa Excite HD; GE Healthcare, Milwaukee, WI) and an 8-channel body-phased
array coil. Respiratory motion was controlled using the breath-hold method at the
end of the expiratory phase. Dynamic MRI was performed with fat-suppressed T1-
weighted gradient-echo imaging and 3-dimensional (3D) acquisition sequences (liver
acquisition with volume acceleration). After pre-enhanced scanning, EOB was ad-
ministered intravenously and 4-phase EOB-enhanced scans of the liver were obtained
during the arterial, portal venous, transitional,25 and hepatobiliary phase (HBP). Scan-
ning during the HBP was performed from 20minutes after the start of EOB injections.
EOB (25 μmol/kg) was administered at a rate of 2.0mL/s and then ﬂushed using 20mL
of saline with a power injector (Sonic Shot 50; Nemoto Kyorindo, Tokyo, Japan). All
of the images were obtained in the transverse plane with an acquisition time of 20
seconds, and 3-mm-thick HBP images were used to generate a functional liver map.
CT acquisition for SBRT planning
Patients were immobilized with a vacuum cushion (Vac-Lok with Wingboard;
CIVCO, Orange City, Iowa), and respiratory motion was coordinated by voluntary
breath-holding in the end of the expiratory phase using an Abches device (Apex
Medical, Tokyo, Japan) that allows patients to control the respiratory motion of the
chest and abdomen. For the simulations, dynamic CT scans (LightSpeed QX/I; GE
Medical Systems, Waukesha, WI) included noncontrast enhancement, and images
in the arterial, portal, and venous phases were collected following the bolus injec-
tions of nonionic iodinated contrast material (100mL at 3mL/s). CT slice thicknesses
were 1.25 to 2.5 mm.
Functional liver map construction
Functional liver maps were generated using a 4-step procedure based on the
EOB-MRI and SBRT planning CT images (Fig. 1). Both image types were acquired before
the radiation planning, and assessments of liver function were performed using the
EOB-MRI and planning CT images as a spatial reference. At ﬁrst deformable
registration, EOB-MRI was spatially aligned using planning CT with an insight seg-
mentation and registration toolkit.26 For median ﬁltering, the EOB-MRI images were
smoothed using a 3D median ﬁlter (15 × 15 × 15mm). For liver-spleen contrast ratio
(LSC) conversion, the MRI signals were then converted to a functional map accord-
ing to quantitative LSC. The pixels of the EOB-MRI images were divided according
to spleen signal intensities, which were measured manually using the volumetric
region of interest. Functional liver was deﬁned as quantitative LSC ≥ 1.5 during the
HBP as described previously.27 Functional liver maps were posterized from grada-
tion images to stepped images by rounding of the numbers to the nearest decimal
point for ease of analysis (> 1.0 but < 1.1, rounded to 1.0; > 1.1 but < 1.2, rounded to
1.1). Finally, because a treatment planning system does not accommodate decimal
numbers on images, the functional map values were multiplied by 1000.
SBRT planning
RT planning CT and EOB-MRI images from 20 patients were transferred to a 3D
treatment planning system (Pinnacle3 ver. 9.6; Phillips Medical Systems, Fitch-
burg, WI). The EOB-MRI images were then fused with the planning CT images that
were obtained during the arterial phase.
Gross tumor volumes (GTVs) were deﬁned as those carrying residual lipiodol
using transarterial chemoembolization and early enhancement during the arterial
phase of dynamic CT. A clinical target volume (CTV) margin of 0 to 5 mmwas added
to the GTV for subclinical invasions, and a planning target volume (PTV) margin of
5 to 8mmwas added to the CTV based on the reproducibility of respiratory motions
and setup errors. Eight ports were selected in all patients, including 4 coplanar and
4 noncoplanar static beams, which were established in directions that avoided the
stomach, intestine, gall bladder, and spine, if possible. Treatment plans were deliv-
ered using 6- and 10-MV photons generated by a linear accelerator (Clinac iX; Varian
Medical Systems, Palo Alto, CA). The total prescribed dose was 48 gray (Gy) in 4 frac-
tions and the prescription dose was delivered to 95% of the PTV.
SBRT plans were subsequently designed using a “step-and-shoot” static IMRT
technique for each patient. First of all, the anatomical SBRT plan (plan A) was op-
timized based on total liver volume using the clinical optimization parameters. Plan
A’s optimization parameters were copied in the functional SBRT plan (plan F), and
then the functional liver map (volume) was added to the dose constraints of plan
F. Finally, plan F was re-optimized based on the functional liver volume. Table 2 shows
the dose constraints for plans A and F, which had exactly the same IMRT opti-
mized values for each patient but different functional liver values.
IMRT inverse treatment planning was optimized using a direct machine param-
eter optimization algorithm. Dose calculations were performed using a 2 × 2 × 2mm
dose grid and a dose computation with collapsed cone convolution.
Data analysis and statistical methods
Dosimetric parameters of plans A and F were investigated by (1) PTV doses to
95% of the prescription dose (PTV D95%) and mean PTV dose; (2) calculating mean
doses to total and functional liver minus GTVs (MLD and fMLD), respectively; (3)
expressing percentages of total and functional liver volumes, which received doses
from 5 to 30 Gy (V5 to V30, fV5 to fV30); (4) calculating mean doses, doses to 0.5 cc
and to 5 cc volumes (D0.5cc and D5cc) of the stomach, duodenum, and intestine;
and (5) calculating monitor units.
Statistical analyses were performed using R-statistics program version 3.1.2 (The
R Foundation for Statistical Computing, Vienna, Austria). Differences were identi-
ﬁed using paired t-tests and considered signiﬁcant at values of p < 0.05. All quantitative
data are expressed as mean ± standard deviation.
Table 1
Patient and tumor characteristics
Age Median/(range) 73/(55-84)
Sex Male/Female 12/8
Performance status 0/1 18/2
Type of virus infection HCV/HBV/NBNC 18/1/1
Child-Pugh class A/B 17/3
Child-Pugh score 5/6/7/≥ 8 10/7/3/0
Clinical stage [UICC Seventh] I/II 14/6
TMN T1N0M0/T2N0M0 14/6
Tumor location S3/S4/S5/S6/S7/S8 2/3/1/4/4/6
GTV (cm3) Median/(range) 1.7/(0.03-27.6)
PTV (cm3) Median/(range) 16.2/(2.4-87.3)
GTV, gross tumor volume; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC,
nonhepatitis B nonhepatitis C; PTV, planning target volume; S, segment of liver; UICC,
International Union Against Cancer.
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Results
Comparison of dosimetric parameters for PTV
Dosimetric parameters including PTV D95% (mean: plan A, 48.0;
plan F, 48.0 Gy; p = 0.78) andmean PTV doses (mean: plan A, 54.6 Gy;
and plan F, 54.8 Gy; p = 0.11) did not differ signiﬁcantly between the
2 plans.
Comparison of dosimetric parameters for total and functional livers
Compared with plan A, plan F signiﬁcantly reduced MLD (mean:
plan A, 5.5 Gy; plan F, 5.1 Gy; p < 0.0001) and fMLD (mean: plan A,
5.4 Gy; plan F, 4.9 Gy; p < 0.0001) as well as total and functional liver
V5 to V30 and fV5 to fV30whilemaintaining the target dose coverage.
Moreover, plan F, which was optimized additionally with func-
tional liver volume, reduced the numbers of low-dose areas (Figs. 2
(A)
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Fig. 1. Protocol for generating functional liver maps based on planning CT and gadoxetate disodium-enhanced magnetic resonance imaging (EOB-MRI). (A) Deformable
registration: basal image (grayscale), planning CT; overlaid color image, EOB-MRI. (B) Median ﬁltering: (left) preﬁltering EOB-MRI; (right) postﬁltering EOB-MRI. (C) Liver-
spleen contrast ratio conversion; EOB-MRI pixels divided by the spleen’s signal intensity. (D) Posterization: EOB-MRI before (upper left) and after (upper right) posterization;
colored EOB-MRI before (lower left) and after (lower right) posterization.
Table 2
Dose constraints for anatomical and functional intensity modulated radiotherapy plans
ROI Plan A: Anatomical plan Plan F: Functional plan
Constraint Dose (cGy) Volume (%) Weight Constraint Dose (cGy) Volume (%) Weight
GTV
Max DVH 6100 0 1 6100 0 1
Min DVH ✓ 6000 1 ✓ 6000 1
Min DVH 5000 90 1 5000 90 1
PTV
Max DVH 6100 0 80 6100 0 80
Max DVH 4848 95 100 4848 95 100
Min DVH ✓ 4800 95 ✓ 4800 95
Min Dose 4320 — 100 4320 — 100
PTV + 20 mm_ring
Max DVH 2000 0 80 2000 0 80
PTV + 5 mm_ring
Max DVH 4300 0 50 4300 0 50
Max DVH 2000 50 10 2000 50 10
Spinal cord
Max DVH 1200 0 10 1200 0 10
Stomach
Max DVH 1800 0 10 1800 0 10
Liver−GTV
Max DVH 2000 5 1-5 2000 5 1-5
Liver_avoid
Max DVH 1800 5 5 1800 5 5
Functional liver−GTV
Max DVH 1800 5 1-5
Functional liver_avoid
Max DVH 1500 5 5
GTV, gross tumor volume; Liver_avoid, add ring-shaped 10-mm-thick ROI to PTV and then the ROI is avoided interior to total liver; Max DVH, maximum dose-volume his-
togram; Min DVH, minimum dose-volume histogram; PTV, planning target volume; PTV + 20 mm_ring, ring-shaped ROI margin of 20 mm is added to PTV; ROIs, regions of
interest.
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and 3; arrows) and spared the functional hepatic parenchyma. Dose-
volume histograms of patients with small functional liver volumes
(Fig. 3B) show marked reductions in mean liver doses, particularly
in fMLD, compared with patients with large functional liver volumes
(Fig. 2B).
Comparison of dosimetric parameters for gastrointestinal organs
Meandose,D0.5cc, andD5ccof thestomach (mean:planA,0.82Gy;
plan F, 0.78 Gy;p = 0.19;D0.5cc: planA, 6.0 Gy; plan F, 5.8 Gy;p = 0.34;
D5cc: planA, 4.5 Gy; plan F, 4.4 Gy; p = 0.36), duodenum (mean: plan
A, 0.59 Gy; plan F, 0.62 Gy; p = 0.09; D0.5cc: plan A, 2.2 Gy; plan F,
2.4 Gy; p = 0.07; D5cc: plan A, 0.96 Gy; plan F, 0.98 Gy; p = 0.4), and
intestine (mean: plan A, 0.68 Gy; plan F, 0.66 Gy; p = 0.29; D0.5cc:
plan A, 4.5 Gy; plan F, 4.7 Gy; p = 0.36; D5cc: plan A, 3.1 Gy; plan F,
3.1 Gy; p = 0.45) were not signiﬁcantly different in the two plans.
However, monitor units (mean: plan A, 2437; plan F, 2495; p = 0.01)
and conformity indexes (mean: plan A, 0.99; plan F, 1.01; p = 0.003)
differed signiﬁcantly between the 2 plans. Comparison of the dosi-
metricparametersbetweenplanAandplanF is summarized inTable3.
Fig. 2. Comparisons of the dose distribution maps and dose-volume histograms between anatomical stereotactic body radiation therapy (SBRT) (plan A) and functional
SBRT plans (plan F) in a patient (patient E) with a large functional liver volume; 69% of total liver: cyan. (A) Dose distribution maps of axial, sagittal, and coronal sections of
plan A (upper) and plan F (lower) are presented. The isodose line at 14.4 Gy (almond) is signiﬁcantly reduced (red arrows) in the functional plan. (B) Dose-volume histo-
grams of plan A (dash line) and plan F (solid line) for patient E. Planning target volume (PTV) and gross tumor volume (GTV) did not differ signiﬁcantly between the 2
plans; however, mean doses to total and functional liver minus GTV of the 2 plans were signiﬁcantly reduced in plan F.
Fig. 3. Comparison of dose distribution maps and dose-volume histograms between anatomical SBRT (plan A) and functional SBRT plans (plan F) in patient A with a small
functional liver volume; 28% of total liver: green. (A) Dose distribution maps of axial, sagittal, and coronal sections of plan A (upper) and plan F (lower) are shown. Isodose
lines at 14.4 (almond) and 24 Gy (cyan) are clearly reduced (red arrows) in the functional plan. (B) Dose-volume histogram of plan A (dash line) and plan F (solid line) for
patient A. Planning target volume (PTV) and gross tumor volume (GTV) did not differ between the 2 plans; however, mean doses to total and functional liver minus GTV
were clearly decreased in plan F.
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Discussion
The present simulation study shows the ability of functional EOB-
MRI–guided liver SBRT planning with IMRT technique to spare
functional liver.
SPECT scintigraphic methods are currently the only imaging-
based liver function tests that are used in clinical practice and are
predominantly performed using 99mTc-iminodiacetate analogs. Al-
though SPECT with 99mTc-mebrofenin or 99mTc-galactosyl human
serum albumin indicates hepatic function, it is diﬃcult to use in con-
junction with SBRT, reﬂecting limitations such as low temporal and
spatial image resolution,28 inability to control internal organ motion
during long scan periods, additional radiation dose exposure, and
cost. In contrast, EOB-MRI has the potential to quantify liver per-
fusion and function, and is commonly used in many institutions.
Approximately 50% of the EOB is taken up by hepatocytes after in-
jection into normal human livers,29,30 allowing the distinction of
functional (EOB-loaded) and dysfunctional liver parenchyma.31,32 The
enhancement of the liver at EOB-MRI depends on liver perfusion,
vascular permeability, extracellular diffusion, and hepatocyte trans-
porter expression.33 Additionally, Verloh et al. demonstrated the
utility of EOB-MRI and relative EOB-MRI enhancement during the
HBP as image-based tests of regional and global liver function.22
Among the advantages of EOB-MRI guidance for liver SBRT is that
EOB-MRI immediately distinguishes between functional and dys-
functional liver tissues with accuracy similar to that of SPECT. Geisel
et al. suggested that EOB-MRI and 99mTc-mebrofenin hepatobiliary
scintigraphy can be used to separately determine right and left liver
lobe function.34
EOB-MRI can also be applied to SBRT planning for HCC. Because
the liver can move substantially because of breathing, breath-
holding or immobilization techniques must be used to obtain high-
quality image registration between functional image sets and
treatment planning sets. In particular, MRI scanning takes approx-
imately 20 seconds, enabling control of the liver motion during the
end-expiratory phase as performed for planning CT. Other advan-
tages of EOB-MRI include the absence of radiation and relative cost-
effectiveness comparedwith positron emission tomography or SPECT.
Furthermore, EOB-MRI can be used routinely in clinical practice
because most hospitals have MRI instruments.
Different EOB-MR imaging parameters, such as LSC, corrected
liver-enhancement ratio, and contrast enhancement indexes, have
been used as imaging-based liver function and ﬁbrosis markers.35,36
However, which of the various existing imaging markers would
provide the most accurate information on liver function is a matter
of much controversy and debate. In this study, functional liver maps
were generated according to quantitative LSC ≥ 1.5 in the HBP as
described byMotosugi et al.27,37 According to their studies, the quan-
titative LSC during HBP appears to have a statistically signiﬁcant
correlation with indocyanine green clearance test and Child-Pugh
classiﬁcation. Moreover, patients with quantitative LSC of more than
1.5 have been evaluated with good or excellent score of visual LSC.37
This study indicated that EOB-MRI–guided functional imaging
modality can be applied to liver SBRT to distinguish functional liver
regions. Moreover, in a prospective study by Shirai et al., 3D con-
formal radiotherapy using SPECT with 99mTc-galactosyl human
serum albumin was shown to be well tolerated by patients with
unresectable HCC and portal vein tumor thrombi, and no patients
experienced RILD.20 Hence, EOB-MRI–guided SBRT plan for the liver
could be a clinically applicable technique and be used to mini-
mize doses to normal liver tissues. Further prospective clinical trial
is needed to demonstrate the clinical impact of the functional SBRT
plan.
In this study, the dose constraints of PTV, normal liver, and
nonhepatic organs at risk (OARs) complied with protocol of the Ra-
diation Therapy Oncology Group 1112 clinical trial of SBRT for HCC
and recommendation of the Quantitative Analyses of Normal Tissue
Effects in the Clinic to reduce the risk of hepatic and gastrointes-
tinal toxicity. The Quantitative Analysis of Normal Tissue Effects in
Clinic recommendations for liver SBRT are as follows: MLD (liver
minus GTV) should receive < 13 Gy for HCC, in 3 fractions; < 18 Gy
for HCC, in 6 fractions; < 6 Gy for HCC, Child-Pugh B, in 4 to 6 Gy
per fraction, or that MLD of ≥ 700mL of normal liver should receive
≤ 15 Gy in 3 to 5 fractions.11
The protocol of Radiation Therapy Oncology Group 1112 liver
trial recommends “reducing the maximal dose to all luminal gas-
trointestinal normal tissues should be a planning priority tominimize
the risk of gastrointestinal toxicity.” The following gastrointesti-
nal organ dose constraints were recommended by the protocol:
maximum dose for stomach, duodenum, and intestine should
receive < 30 Gy to 0.5 cc and < 25 Gy to 5 cc separately.38
The present results showed that total and functional liver mean
doses (MLD, fMLD) and nonhepatic OARs doses were much lower
than their dose constraints. Stomach, duodenum, and intestine doses,
which are OARs of interest with liver SBRT, were not signiﬁcantly
different in the 2 plans (Table 3).
Furthermore, this study demonstrated that an excellent dose
distribution and preserving functional liver can be made by func-
tional EOB-MRI–guided SBRT planning using IMRT technique. It
was able to make an excellent dose distribution and to reduce dose
to the functional liver, as well as the total liver by optimizing ad-
ditional dose constraints for the functional liver with IMRT inverse
planning technique. The current results showed that the degree of
Table 3
Comparison of dosimetric parameters between anatomical and functional plans
ROI Plan A Plan F p-value
PTV:
D95 (Gy) 48.0 ± 0.02 48.0 ± 0.015 0.78
Mean dose (Gy) 54.6 ± 0.55 54.8 ± 0.62 0.11
Conformity index 0.99 ± 0.06 1.01 ± 0.07 0.003
Total liver GTV:
Mean dose (Gy) 5.5 ± 2.7 5.1 ± 2.7 <0.0001
V5 (%) 30 ± 14 27 ± 14.6 0.0002
V10 (%) 18 ± 11 16 ± 11 <0.0001
V15 (%) 11 ± 7.6 9.4 ± 6.4 0.0004
V20 (%) 6.6 ± 4.4 6.3 ± 4 0.006
V25 (%) 4.6 ± 2.9 4.5 ± 2.9 0.01
V30 (%) 3.53 ± 2.2 3.46 ± 2.2 0.03
Functional liver GTV:
Mean dose (Gy) 5.4 ± 2.9 4.9 ± 2.7 <0.0001
fV5 (%) 31 ± 18 28 ± 17 0.002
fV10 (%) 18 ± 12 15 ± 10 0.0006
fV15 (%) 10.6 ± 7.6 8.7 ± 5.5 0.001
fV20 (%) 6.4 ± 4.2 5.7 ± 3.6 0.01
fV25 (%) 4.4 ± 2.8 4.2 ± 2.6 0.01
fV30 (%) 3.3 ± 2 3.1 ± 1.9 0.01
Stomach
Mean dose (Gy) 0.82 ± 0.76 0.78 ± 0.78 0.19
D0.5cc (Gy) 6.0 ± 5.0 5.8 ± 5.5 0.34
D5cc (Gy) 4.5 ± 4.5 4.4 ± 4.9 0.36
Duodenum
Mean dose (Gy) 0.59 ± 0.96 0.62 ± 1 0.09
D0.5cc (Gy) 2.2 ± 3.7 2.4 ± 4 0.07
D5cc (Gy) 0.96 ± 2.4 0.98 ± 2.5 0.4
Intestine*
Mean dose (Gy) 0.68 ± 1.1 0.66 ± 1 0.29
D0.5cc (Gy) 4.5 ± 5.7 4.7 ± 6.4 0.36
D5cc (Gy) 3.1 ± 4.4 3.1 ± 4.8 0.45
Monitor unit 2437 ± 366 2495 ± 378 0.01
D0.5cc, dose to 0.5 cc volumes; D5cc, dose to 5 cc volumes; D95, dose to 95% of PTV;
fV5 to fV30, percentage of functional liver volumes, which received doses from 5
to 30 Gy; GTV, gross tumor volume; Plan A, anatomical plan; Plan F, functional plan;
PTV, planning target volume; ROI, region of interest; V5 to V30, percentage of total
liver volumes, which received doses from 5 to 30 Gy.
* Intestine includes small and large bowels.
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functional preservation depends on functional liver tissue location
and volume, as well as tumor location and size. Speciﬁcally, func-
tional image-guided SBRT planning was more eﬃcient in patients
with small functional liver volumes (Fig. 3) than in those with large
functional liver volumes (Fig. 2). Previous studies also demon-
strated the dependence of dosimetric beneﬁts on functional region
location and volumes,14,39 with greater dosimetric preservation of
functional lung tissues in patients with heterogeneous functional
distributions that do not completely surround the target. More-
over, Lavrenkov et al. showed that IMRT led to greater preservation
of the functional lung volume when the functional lung was located
proximal to the PTV and when the overall functional distribution
was more heterogeneous.39
Accurate image registration and delineation of targets and normal
tissues are critical to the utility of functional image guidance during
RT planning. Thus, we generated a functional liver map with high
spatial resolution and image resolution using the methods pre-
sented above and demonstrated the ease of fusing EOB-MRI images
to planning CT images and delineating the functional liver map.
The main limitation of the current study is that it is only a sim-
ulation study on a small cohort, warranting further prospective
clinical trials of large patient populations. Second, the registration
of EOB-MRI and RT planning CT images was compromised by im-
perfect image matching in some cases, for which the deformable
imaging software requiredmanual adjustments to achieve high focus
on the target, vessel, and peripheral shape areas. Finally, the func-
tional liver regions were determined using a binary quantitative
criterion (LSC ≥ 1.5). Thus, the inclusion of additional imagingmarkers
in further analyses would be beneﬁcial to deﬁne quantitatively the
functional heterogeneity.
Conclusions
This simulation study demonstrates the ability of functional
imaging with EOB-MRI for SBRT planning in patients with HCC. EOB-
MRI–guided SBRT planning using the IMRT technique may improve
functional liver preservation in patients with HCC.
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